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Background/aim: The aim of our study was to check how MGMT methyla-
tion status together with known factors inﬂuenced the risk of colon cancer
development.
Materials and methods: We  examined patients with colon polyps. Information concerning
gender, age, lifestyle, diet, anthropometry and medical information, including cancer and
family history of cancer, was analyzed. Polymorphism variety of MGMT gene was investi-
gated in another study. Genetic analysis for MGMT methylation assessment was performed
for  polyp tissue samples from 143 patients.
Results: Positive methylation MGMT status was found in 55 patients. There was no correlation
between gender and MGMT methylation status (p = 0.43). We  did not ﬁnd correlation between
patients younger and older than 60 (p = 0.87). There was no correlation between smoking and
MGMT methylation status (p = 0.36). We  did not ﬁnd correlation between BMI and MGMT
methylation status (p = 0.86). We  did not ﬁnd correlation between MGMT methylation status
and colon cancer in familial history (p = 0.45).
Conclusion: Our study showed no correlations between methylation status of MGMT
polymorphisms and clinical features like age, gender, polyp localization, smoking sta-
tus,  or obesity. It has been shown previously that MGMT methylation status may
show nonspeciﬁc methylation in colon polyps. Gene methylation status in adenoma
tissues has also been associated by other authors with the adenoma’s size, histol-
ogy, and degree of atypia. In our study, we evaluated the gene methylation statusin  colon polyps and found no association with adenoma characteristics. The present
study showed no correlation for MGMT methylation in polyps in different regions of
colon.
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1.  Background
MGMT  promoter methylation is presented in approximately
20–30% of colorectal cancers and in many  of them it coexists
with or in some cases is independent of CIMP status. Tran-
scriptional inactivation by promoter CpG island methylation
tumor suppressor genes is an important mechanism in human
carcinogenesis.1–3 Epigenetic suppressor gene silencing has
commonly been involved in all types of human tumors.4–6
The inactivating of tumor suppressor genes may affect many
important cellular processes, such as the cell cycle, the TP53,
the WNT  signaling pathways, DNA repair, apoptosis pathways
and the metastasizing process.1–3 The human MGMT  gene is
located on chromosome 10q26 and consists of 5 exons. MGMT
is a DNA repair protein that removes adduct from 06 –G in
DNA. The same effect is observed in many  types of human
tumors where the lack of MGMT  expression results in higher
frequency of mutations in genes critical for carcinogenesis,
such as K-ras2 and p53.7–9 Mutations in MGMT have rarely
been found, and it has been suggested that MGMT inactivation
is primarily manifested through hypermethylation-induced
silencing of its promoter in human cancers, including those
of the colon.10–12
We  explored these potential biomarkers using methylation
speciﬁc PCR (MSP) assay approach to measure the methylation
status of MGMT  gene in colon polyps. Then we  examined the
MGMT  methylation status and correlations between clinical
features like age, gender, polyp localization, smoking status,
obesity and sporadic polyps characteristics.
2.  Aim
The aim of the study was to establish the role of methylation
status in colon polyps.
3.  Materials  and  methods
The cases were recruited from colonoscopy department of the
Greater Poland Cancer Centre between the years 2004–2008.
Patients were chosen randomly; there was only one cri-
terion for inclusion into the study: having a colon polyp.
Volunteers were outpatients with no known gastrointestinal
pathology who had undergone colonoscopy as a diagnos-
tic procedure, typically to investigate nonspeciﬁc symptoms,
such as abnormal bowel habit or unexplained rectal bleed-
ing. Ethical approval for the project was received from the
Institutional Review Board at Poznan University of Medical
Sciences (local Research Ethics Committee, project reference
965/08) and the consent was obtained in advance of the
expected date of endoscopy. Information concerning gender,
age, lifestyle, diet, anthropometry and medical information,
including cancer and family history of cancer, was obtained
from a questionnaire. Experimental biopsies were collected
from the endoscopy patients in the endoscopy department,
immediately after procedure. All colon polyps were divided
into two parts, one underwent histopathological estimation
and the other one served as material for DNA extrac-
tion. All polyps were examined twice by two independentdiotherapy 1 7 ( 2 0 1 2 ) 13–18
pathologists. Polymorphism variety of MGMT gene was inves-
tigated in another study.
3.1.  Genetic  analysis
Methylation-speciﬁc PCR. Bisulﬁte modiﬁcation: DNA (1 g) in
volume of 50 l was denatured by NaOH to ﬁnal concentration
of 0.2 M for 10 min  at 37 ◦C. Thirty microliters of 10 nM hydro-
quinone and 520 l of 3 M sodium bisulﬁte at pH 5 were mixed
and added to the sample and incubated at 50 ◦C for 16 h. Modi-
ﬁed DNA was puriﬁed using the Wizard DNA puriﬁcation resin
according to the manufacturer protocol (Promega) and eluted
into 50 l of water. Modiﬁcation was completed by NaOH (ﬁnal
concentration of 0.3 M) incubation for 5 min  at room tempera-
ture, followed by ethanol precipitation. DNA was resuspended
in water and before PCR reaction, concentration of DNA was
measured.
MGMT ampliﬁcation: The following sets of primers
were used for ampliﬁcation: UM F: 5′-TTTGTGTTTT-
GATGTTTGTAGGTTTTTGT; UM R: 5′-AACTCCACACTCTTCC-
AAAAACAAAACA; M F: 5′-TTTCGACGTTCGTAGGTTTTCGC
and M R: 5′-GCACTCTTCCGAAAACGAAACG.
PCR-SSCP analysis was performed for polyp tissue sam-
ples from 143 patients according to the MSP  method.
We used TaqPol (Applied Biosystem) polymerase, and
primer sequences of MGMT  for the unmethylated reaction
F were: 5′-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3′ (upper
primer) and R: 5′-AACTCCACACTCTTCCAAAAACAAAACA-3′
(lower primer) and for the methylated reaction F: 5′-
TTTCGACGTTCGTAGGTTTTCGC-3′ (upper primer) and R:
5′-GCACTCTTCCGAAAACGAAACG-3′ (lower primer). Each PCR
mixture contained a buffer (10×), MGCl2 (2 nM), dNTP (300 M),
F (50 pM), R (50 pM), TaqPol (5 U), and DNA matrix (200 ng). Vol-
ume  of reaction was 10 l. The annealing temperature was
59 ◦C.
3.2. Statistical  analysis
The Pearson’s chi-square (2) and Fisher’s exact tests were
used to test the differences in genotype and allele (respec-
tively) distribution between patients and control subjects.
Statistical analyses were performed using Statistica v.7.1 soft-
ware (Statsoft, USA). For polymorphisms containing less than
5 observations per cell, the Fisher–Freeman–Halton exact test
was performed using StatsDirect statistical software v.2.6.2.
Logistic regression was employed to calculate odds ratios (OR)
and 95% conﬁdence intervals (95%CI) and used to calculate
interactions. Odds ratios were calculated using a demonstra-
tion version of GraphPad InStat 3.
4.  Results
Our study group consisted of 74 males (51.75%) and 69 females
(48.25%). The median age in our group was 60.32. The main
aim of our study was to check how MGMT  methylation sta-
tus together with known factors inﬂuenced the risk of colon
cancer development. Positive methylation MGMT  status was
found in 55 patients. There was no correlation between gender
and MGMT methylation status (p = 0.43). Patients were divided
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 13–18 15
Table 1 – Clinical and histipatological factors and MGMT  methylation status.
Factor All Methylated p OR, 95%CI
Gender Female  69 23 0.4314 0.7708
Male 74 32 0.4112–1.448
Age ≤60 68 25 0.874 0.9191
>60 75 30 0.4924–1.716
BMI ≤25 98 39 0.8638 1.119
>25 45 16 0.5666–2.211
Tobacco users Smokers 39 11 0.3623 0.6667
Non-smokers 104 44 0.3129–1.42
Familial history Colon cancer 17 4 0.4449 0.5813
Others 126 51 0.1865–1.812
Familial history Non colon cancer 84 31 0.8724 0.9072
Others 59 24 0.4839–1.701
Polyps Hyperplastic 42 14 0.599 0.8
Adenomatous 96 41 0.3939–1.625
Polyps size ≤5  mm 122 48 0.8227 1.18
>5 mm 21 7 0.4711–2.957
Polyps localization Distal  colon 108 41 1 0.9491
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nto two groups: aged 60 and younger and older than 60. We  did
ot ﬁnd correlation between patients younger and older than
0 (p = 0.87). In the study group, there were 39 smokers and 104
on-smokers. There was no correlation between smoking and
GMT  methylation status (p = 0.36). Obesity was also regarded
s a risk factor of polyp formation. 98 patients were found
o have a BMI  higher than 25 and we did not ﬁnd correlation
etween BMI  and MGMT  methylation status (p = 0.86). More-
ver, all patients followed the same diet, typical for Central
urope.
In our group, the polyps were localized in the rectum (39;
7.4%), sigmoid colon (60; 41.9%), descending colon (9; 6.3%),
ransverse colon (17; 11.9%), ascending colon (12; 8.4%) and
ecum (6; 4.2%). We  expected the methylation status of MGMT
ene to show association with proximal localization but no
tatistical evidence was noticed to prove it (p = 1.00). Among
istological types of polyps, the biggest group was adenomas
ecognized in 96 (67.1%) cases, followed by hiperplastic polyps
ith 42 (29.4%) cases. Other types, such as mixed polyps and
errated polyps, were recognized in 2 (1.4%) and 3 (2.1%) cases,
espectively (2 sessile serrated adenoma and 1 traditional ser-
ated adenoma).
Adenomatous and hiperplastic polyps share the same risk
actors, such as age, sex, smoking and alcohol consumption.
ge is the risk factor for adenomatous polyps while smok-
ng for hyperplastic. We  analyzed how MGMT methylation
ogether with age and smoking modulated the risk of develop-
ng each of polyp type, but found no correlation between age,
moking, MGMT  methylation status and type of colon polyps.
For further statistical analysis, the two groups of high
isk polyps were appreciated based on size. The ﬁrst group
ncluded 21 polyps larger than 5 mm;  no correlation was found
etween this group and smoking (p = 1.00), age (for patients
lder than 60, p = 0.38), gender (p = 0.72) and MGMT methy-
ation status was. Among 84 patients who declared cancer14 0.4635–1.943
cases in close relatives, 17 colon cancers were found in familial
history. Moreover, 3 patients fulﬁlled the criterion of HNPCC
syndrome. Familial colorectal cancer was deﬁned broadly to
include colorectal cancer patients who have at least one
ﬁrst-degree relative with colorectal cancer. We  did not ﬁnd cor-
relation between MGMT methylation status and colon cancer
in familial history (p = 0.45). Nor did we ﬁnd any association
between other types of cancers reported in family history
(p = 0.87). Results of the statistical analysis are presented in
Tables 1 and 2.
5.  Discussion
Colorectal cancers develop as a result of the transformation
of normal mucosal epithelium to cancer through precur-
sor lesions with genetic and epigenetic changes. Promoter
methylation of several genes has been found to be limited
to colorectal cancers. It has been observed in tumor sup-
pressor genes and DNA repair genes such as MGMT.13,14
Ogino et al.15 investigated the connection between MGMT
germline SNPs and promoter methylation in colorectal can-
cer. A strong association was found between c.−56C > T and
promoter methylation and MGMT silencing. Unfortunately,
non-promoter polymorphisms, as L84F, did not show such sig-
niﬁcant correlation.
The aging process and varying exposures to environ-
ment have been hypothesized to cause signiﬁcant changes in
methylation proﬁles.22 Recent research has shown an over-
all trend of increased methylation in several genes associated
with older age in normal colon tissues.20 Age-dependent
methylation in healthy human colon may contribute to an
increased risk of colorectal cancer.20,23 In some studies,
authors observed the contrary, that is they found no cor-
relation with age.19,24 Yamashita at al. proposed that all
16  reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 13–18
Table 2 – Colon polyps localization and MGMT methylation status.
Polyps Methylated p OR, 95%CI
Recti 39  12 0.4733 0.7442
104 43 0.3556–1.557
Sigmae 60 25 0.7488 1.153
83 30 0.6163–2.156
Descending colon 9  4 0.7573 1.168
134 51 0.3443–3.961
Transverse colon 17 6 1.000  0.9076
126 49 0.3380–2.437
Ascending colon 12  7 0.4194 1.592
131 48 0.5920–4.282
Ceci 6 1 0.6758 0.4228
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methylation statuses in colorectal cancers were related only
to the aging process, non neoplastics.25 Our data did not
suggest that MGMT  was methylated in an age-dependent
manner. There was no correlation between MGMT methy-
lation status and age in our study group. Our data were in
accordance with the observation of Eckhardt et al.26 There was
no changes in DNA methylation over time. In that study, values
were averaged across individuals for a given age group.
These ﬁndings may indicate that there are differences
between populations, perhaps because of genotyping varia-
tion or differing exposure to environmental factors, such as
diet. Bjornsson et al. suggest more  complex associations.24
These authors found both increased and decreased intra-
individual global methylation levels (promoter regions) in
peripheral blood cell DNA over time. In this context, it is
crucial to more  extensively characterize the contribution
of aging and the environment to tissue-speciﬁc epigenetic
proﬁles.
Ahlquist et al.27 identiﬁed methylation proﬁles of normal
colorectal tissues, adenomas and carcinomas. The results
demonstrated a stepwise increase in CpG island promoter
methylation towards malignancy. Taken together, these obser-
vations suggest that methylation levels in the normal colonic
mucosa could serve as markers of risk for the development of
colon adenomas and colorectal cancer. Animal studies have
shown that a loss of DNA methylation increases intestinal
adenoma initiation and a gain of DNA methylation increases
adenoma progression.28 Similarly, both hypomethylation and
hypermethylation could lead to autoimmune disease by acti-
vating autoreactivity genes or silencing histocompatibility
genes.29 Other previous studies have evaluated the rela-
tionship between methylation and other clinicopathological
characteristics of adenomas.30
In our study, colon polyps were divided according to dis-
tal or proximal colon localization, localization according to
the colon topography, size and histological types of polyps
(hiperplastic versus adenoma). We  did not observe correlation
between MGMT  methylation status and these markers.
Another salient ﬁnding of our analysis was the higher
frequency of MGMT  methylation among subjects who were
overweight or obese (BMI ≥ 25). To our knowledge, this study
is the ﬁrst to report an association between overweight/obesity0.04971–3.597
and an increased frequency of MGMT methylation. We did
not observe correlation between MGMT methylation and
overweight or obesity, but these results are interesting and
warrant investigation in future studies with a larger group of
patients.
Several reports have described an association between the
methylation status of genes and a familial tendency to col-
orectal cancer.31 However, Ward et al. found no evidence
that patients with heavily methylated colorectal cancers were
more  likely to develop a second malignancy or have a positive
family history of cancer.32 Aberrant methylation may result
from an inherited defect in the methylation. In this study,
there were no differences between the groups with or without
familial history of colorectal cancer who presented the posi-
tive MGMT methylation status. It still remains to be elucidated
whether promoter methylation in some genes is one of the
main mechanisms to evoke cancer or is purely coincidental.
To acquire signiﬁcance to DNA methylation in cancer and
various other diseases, assays to measure DNA methylation
proved very useful to both research and clinical practice. DNA
methylation of some tumor suppressor genes in breast can-
cer has been shown to be predictive of responsiveness to
tamoxifen therapy.33 It has been proved that methylation and
silencing of the MGMT  gene in glioblastoma are associated
with an increased beneﬁt from temozolomide treatment.6
Regarding all evaluated genes, patients with multiple lesions
exhibited a higher degree of methylation in tumor samples
than those with solitary tumors.34 This epigenetic change
can also be detected in precancerous lesions and seem-
ingly normal peritumor tissues,35 thus suggesting its potential
involvement in the initial carcinogenetic process. A series
of studies investigating the fecal DNA of patients with col-
orectal cancer and adenomas in comparison with samples
from normal individuals revealed a higher rate of methyla-
tion of the target genes in the patients with cancer.36 This
fact clearly demonstrates the need to carefully analyze any
newly detected gene in the context of methylation-silencing
in terms of its role in carcinogenesis. Early cancer detection
and removal of premalignant adenomatous polyps has been
shown to be of fundamental importance and consequence in
preventing death due to colorectal cancer and reducing col-
orectal cancer incidence.37 For patients with colon polyps,
d rad
s
h
p
a
6
U
m
t
o
l
p
a
s
u
n
s
i
o
f
d
o
a
f
C
N
A
T
r
P
p
C
r
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
3reports of practical oncology an
ometimes with unclear clinical manifestation, with family
istory, however detailed histopatological examination of all
resenting polyps, we  search instruments to discern whether
ny of the polyps are at risk from cancerogenesis.
.  Conclusion
nexpectedly, our study showed no correlations between
ethylation status of MGMT  polymorphisms and clinical fea-
ures like age, gender, polyp localization, smoking status, or
besity. It has been shown previously that MGMT methy-
ation status may show nonspeciﬁc methylation in colon
olyps. Gene methylation status in adenoma tissues has
lso been associated by other authors with the adenoma’s
ize, histology, and degree of atypia. In our study, we eval-
ated gene methylation status in colon polyps and found
o association with adenoma characteristics. The present
tudy showed no correlation for MGMT  methylation in polyps
n different regions of the colon. The probable involvement
f MGMT  SNPs is possible via cumulative action of dif-
erent environmental factors or by synchronous effect of
ifferent polymorphisms in other genes. These possibilities
ught to be considered to recognize the true role of MGMT
nd MGMT  methylation status in polyps and colon cancer
ormation.
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